Paper4292247
Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.
Cash R and 3 others. J Clin Endocrinol Metab, 1967. Cited by 284 papers, by iCite.
Cite this record
ConductScience Library. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. Papers, record 4292247. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4292247
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenal Cortex Hormones | Major topic |
| Adrenal Glands | Major topic |
| Anticonvulsants | Major topic |
| Adrenocorticotropic Hormone | |
| Adult | |
| Aminoglutethimide | |
| Animals | |
| Breast Neoplasms | |
| Child | |
| Cholesterol | |
| Clinical Trials as Topic | |
| Cushing Syndrome | |
| Enzyme Therapy | |
| Enzymes | |
| Epilepsy, Absence | |
| Female | |
| Humans | |
| Lyases | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Pregnenolone | |
| Rats |
Source PubMed
Cited by43
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 284 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39821038 | Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy. | Adv Exp Med Biol | 2025 | https://conductscience.org/library/papers/39821038 | PubMed |
| 37931519 | Aromatase enzyme: Paving the way for exploring aromatization for cardio-renal protection. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37931519 | PubMed |
| 29146384 | Identification of candidate reference chemicals for in vitro steroidogenesis assays. | Toxicol In Vitro | 2018 | https://conductscience.org/library/papers/29146384 | PubMed |
| 23625614 | Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. | Endocr Relat Cancer | 2013 | https://conductscience.org/library/papers/23625614 | PubMed |
| 20616198 | The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. | Ann Oncol | 2011 | https://conductscience.org/library/papers/20616198 | PubMed |
| 17973095 | Aromatase inhibitors: past, present and future in breast cancer therapy. | Med Oncol | 2008 | https://conductscience.org/library/papers/17973095 | PubMed |
| 17486453 | Aromatase inhibitors for breast cancer. | Rev Endocr Metab Disord | 2007 | https://conductscience.org/library/papers/17486453 | PubMed |
| 17169390 | Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. | Steroids | 2007 | https://conductscience.org/library/papers/17169390 | PubMed |
| 15203550 | Involvement of steroids in anti-inflammatory effects of PK11195 in a murine model of pleurisy. | Mediators Inflamm | 2004 | https://conductscience.org/library/papers/15203550 | PubMed |
| 12844324 | Clinical pharmacokinetics of aromatase inhibitors and inactivators. | Clin Pharmacokinet | 2003 | https://conductscience.org/library/papers/12844324 | PubMed |
| 12172571 | The role of aromasin in the hormonal therapy of breast cancer. | Pathol Oncol Res | 2002 | https://conductscience.org/library/papers/12172571 | PubMed |
| 10929927 | Is there a growing role for endocrine therapy in the treatment of breast cancer? | Drugs | 2000 | https://conductscience.org/library/papers/10929927 | PubMed |
| 10473018 | Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. | Drugs | 1999 | https://conductscience.org/library/papers/10473018 | PubMed |
| 8883419 | Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8883419 | PubMed |
| 7949205 | First generation aromatase inhibitors--aminoglutethimide and testololactone. | Breast Cancer Res Treat | 1994 | https://conductscience.org/library/papers/7949205 | PubMed |
| 7749129 | Aromatase inhibitor development for treatment of breast cancer. | Breast Cancer Res Treat | 1995 | https://conductscience.org/library/papers/7749129 | PubMed |
| 6986409 | Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. | J Clin Invest | 1980 | https://conductscience.org/library/papers/6986409 | PubMed |
| 6871483 | Aminoglutethimide treatment in advanced breast cancer: an efficient therapy as a late endocrine alternative in a sequential therapeutic approach. | Breast Cancer Res Treat | 1983 | https://conductscience.org/library/papers/6871483 | PubMed |
| 6797571 | Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. | Br Med J (Clin Res Ed) | 1981 | https://conductscience.org/library/papers/6797571 | PubMed |
| 6518295 | Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer. | Breast Cancer Res Treat | 1984 | https://conductscience.org/library/papers/6518295 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4292247
GET https://conductscience.org/api/papers/v1/4292247/cited_by?page=2